Information on EC 1.8.1.12 - trypanothione-disulfide reductase

for references in articles please use BRENDA:EC1.8.1.12
Word Map on EC 1.8.1.12
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Specify your search results
Select one or more organisms in this record:

The enzyme appears in viruses and cellular organisms

top print hide
EC NUMBER
COMMENTARY hide
1.8.1.12
-
top print hide
RECOMMENDED NAME
GeneOntology No.
trypanothione-disulfide reductase
top print hide
REACTION
REACTION DIAGRAM
COMMENTARY hide
ORGANISM
UNIPROT
LITERATURE
trypanothione + NADP+ = trypanothione disulfide + NADPH + H+
show the reaction diagram
top print hide
REACTION TYPE
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
oxidation
-
-
-
-
redox reaction
-
-
-
-
reduction
-
-
-
-
top print hide
PATHWAY
BRENDA Link
KEGG Link
MetaCyc Link
Glutathione metabolism
-
-
Metabolic pathways
-
-
top print hide
SYSTEMATIC NAME
IUBMB Comments
trypanothione:NADP+ oxidoreductase
Trypanothione disulfide is the oxidized form of N1,N8-bis(glutathionyl)-spermidine from the insect-parasitic trypanosomatid Crithidia fasciculata. The enzyme from Crithidia fasciculata is a flavoprotein (FAD), whose activity is dependent on a redox-active cystine at the active centre. (cf. EC 1.8.1.7, glutathione-disulfide reductase)
top
top print hide
CAS REGISTRY NUMBER
COMMENTARY hide
102210-35-5
-
top print hide
ORGANISM
COMMENTARY hide
LITERATURE
UNIPROT
SEQUENCE DB
SOURCE
putative, fragment; human parasite, strain HK9
SwissProt
Manually annotated by BRENDA team
Z
-
-
Manually annotated by BRENDA team
Z
-
-
Manually annotated by BRENDA team
-
-
-
Manually annotated by BRENDA team
clone 5-Rho-SU/59/P
-
-
Manually annotated by BRENDA team
clone 5-Rho-SU/59/P
-
-
Manually annotated by BRENDA team
-
UniProt
Manually annotated by BRENDA team
Lunaria biennis
-
-
-
Manually annotated by BRENDA team
no activity in Homo sapiens
-
-
-
Manually annotated by BRENDA team
Silvio strain
-
-
Manually annotated by BRENDA team
top print hide
GENERAL INFORMATION
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
physiological function
top print hide
SUBSTRATE
PRODUCT                       
REACTION DIAGRAM
ORGANISM
UNIPROT
COMMENTARY
(Substrate) hide
LITERATURE
(Substrate)
COMMENTARY
(Product) hide
LITERATURE
(Product)
Reversibility
r=reversible
ir=irreversible
?=not specified
4-aminobutyryl-L-cysteinylglycyl-3-methylaminopropylamide disulfide + NADPH
?
show the reaction diagram
-
substrate analogue
-
-
?
ajoene + NADPH
?
show the reaction diagram
-
i.e. (E,Z)-4,5,9-trithiadodeca-1,6,11-triene-9-oxide, substrate and inhibitor
-
-
?
benzyloxycarbonyl-L-cysteinylglycyl-3-methylaminopropylamide disulfide + NADPH
?
show the reaction diagram
-
substrate analogue
-
-
?
deazatrypanothione + NADPH
?
show the reaction diagram
-
substrate analogue
-
-
?
glutathionylspermidine disulfide + NADPH
2-glutathionylspermidine + NADP+
show the reaction diagram
L-beta-aspartyl-L-cysteinylglycyl-3-methylaminopropylamide disulfide + NADPH
?
show the reaction diagram
-
substrate analogue
-
-
?
L-cysteinylglycyl-3-methylaminopropylamide disulfide + NADPH
?
show the reaction diagram
-
substrate analogue
-
-
?
L-gamma-glutamyl-L-cysteinylglycyl-3-methylaminopropylamide disulfide + NADPH
?
show the reaction diagram
-
substrate analogue
-
-
?
NADPH + trypanothione disulfide + H+
trypanothione + NADP+
show the reaction diagram
tert-butyloxycarbonyl-L-cysteinylglycyl-3-methylaminopropylamide disulfide + NADPH
?
show the reaction diagram
-
substrate analogue
-
-
?
trypanothione + 5,5'-dithiobis-(2-nitrobenzoic acid)
trypanothione disulfide + thionitrobenzoate
show the reaction diagram
trypanothione + NADP+
trypanothione disulfide + NADPH + H+
show the reaction diagram
trypanothione disulfide + beta-thio-NADPH
trypanothione + beta-thio-NADP+
show the reaction diagram
-
wild-type and mutant enzymes
-
-
?
trypanothione disulfide + NADPH
trypanothione + NADP+
show the reaction diagram
trypanothione disulfide + NADPH + H+
trypanothione + NADP+
show the reaction diagram
trypanothione disulfide + reduced 3-acetylpyridine adenine dinucleotide
trypanothione + oxidized 3-acetylpyridine adenine dinucleotide
show the reaction diagram
-
wild-type and mutant enzymes
-
-
?
additional information
?
-
top print hide
NATURAL SUBSTRATES
NATURAL PRODUCTS
REACTION DIAGRAM
ORGANISM
UNIPROT
COMMENTARY
(Substrate) hide
LITERATURE
(Substrate)
COMMENTARY
(Product) hide
LITERATURE
(Product)
REVERSIBILITY
r=reversible
ir=irreversible
?=not specified
trypanothione disulfide + NADPH
trypanothione + NADP+
show the reaction diagram
trypanothione disulfide + NADPH + H+
trypanothione + NADP+
show the reaction diagram
additional information
?
-
top print hide
COFACTOR
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
3-acetylpyridine adenine dinucleotide
-
-
beta-thio-NADPH
NADP+
additional information
-
enzyme is a flavoprotein
-
top print hide
INHIBITORS
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
(+/-)-10,11-dihydrolunarine
Lunaria biennis
-
0.1 mM
(1,3,5-triaza-7-phosphaadamantane)Au(saccharine)
-
-
-
(1E)-1-(2-chlorophenyl)penta-1,4-dien-3-one
-
0.1 mM, irreversible inhibition
(1E)-1-[2-chloro-10-[3-(dimethylamino)propyl]-10,10a-dihydro-4aH-phenothiazin-8-yl]ethanone O-benzyloxime
-
-
(1E,2E)-3-(5-nitrofuran-2-yl)prop-2-enal N-hexylsemicarbazone
-
-
(1S,3S)-3-(3,4-dichlorophenyl)-N-methyl-2,3-dihydro-1H-inden-1-amine
-
-
(2-chloroethoxy)diphenylmethane
-
-
(22R,25R)-solasodine
-
compound is an alkaloid scaffold lead in the search for inhibitors
-
(22R,25S)-solanidine
-
compound is an alkaloid scaffold lead in the search for inhibitors
-
(22S,25S)-tomatidine
-
compound is an alkaloid scaffold lead in the search for inhibitors
-
(2E)-3-(5-nitrofuran-2-yl)-N-tricyclo[3.3.1.13,7]dec-1-ylprop-2-enamide
-
-
(2E)-N-hexyl-3-(5-nitrofuran-2-yl)prop-2-enamide
-
-
(2Z)-2-[(2E)-2-(3H-indol-3-ylidene)ethylidene]-1-methyl-1,2-dihydroquinoline
-
-
(3'R,4'R)-3'-carbamoyl-1'-(2-oxo-2-[[2-(phenylsulfanyl)phenyl]amino]ethyl)-1,4'-bipiperidinium
(4'-(benzo[b]thiophen-2-yl)-1,4'-bipiperidinyl-1'-yl)(phenyl)-methanone
-
-
(4'-chloro-2,2':6',2''-terpyridine)platinum(II) ammine complex
-
irreversible, altering specifically the Cys52 residue in the active center, increased oxidase activity
(4-picoline) (4'-p-bromophenyl-2,2':6',2''-terpyridine)platinum(II) complex
-
irreversible, altering specifically the Cys52 residue in the active center, increased oxidase activity
(4E)-5-(2-chlorophenyl)-N,N,2,2-tetramethyl-3-oxopent-4-en-1-aminium chloride
-
0.1 mM, reversible inhibition
(4E)-5-(2-chlorophenyl)-N,N-dimethyl-3-oxopent-4-en-1-aminium chloride
-
0.1 mM, irreversible inhibition
(6-benzyloxycarbonylamino-6-[[[methyl-(2-propylamino-ethyl)-carbamoyl]-methyl]-carbamoyl]-1-[[(3-propylamino-propylcarbamoyl)-methyl]-carbamoyl]-hex-3-enyl)-carbamic acid benzyl ester
-
-
(6-benzyloxycarbonylamino-6-[[[methyl-(2-propylamino-ethyl)-carbamoyl]-methyl]-carbamoyl]-1-[[(3-propylamino-propylcarbamoyl)-methyl]-carbamoyl]-hexyl)-carbamic acid benzyl ester
-
-
1,1'-(10-acetyl-10,10a-dihydro-4aH-phenothiazine-2,8-diyl)diethanone
-
-
1,1'-hexamethylenebis[5-(4-chlorophenyl)biguanide]
-
more than 90% inhibition at 0.1 mM
1,1'-[10-[3-(dimethylamino)propyl]-10,10a-dihydro-4aH-phenothiazine-2,8-diyl]diethanone
-
-
1,1'-[ethane-1,2-diylbis(oxyethane-2,1-diyl)]bis(3-benzyl-1,3-dihydro-2H-benzimidazol-2-imine)
-
-
1,1'-[methanediylbis(oxyethane-2,1-diyl)]bis(3-methyl-1,3-dihydro-2H-benzimidazol-2-imine)
-
IC50: 0.1 mM
1,1'-[methanediylbis(oxyethane-2,1-diyl)]bis(3-phenyl-1,3-dihydro-2H-benzimidazol-2-imine)
-
IC50: 0.004 mM
1,3-Bis(2-chloroethyl)-1-nitrosourea
-
-
1,3-bis[3-(dimethylamino)propyl]-1,5-dihydro-2H-pyrimido[4,5-beta][1,4]benzothiazine-2,4(3H)-dione
1,6-dimethyl-3-(4-methylphenyl)pyrimido[5,4-e][1,2,4]triazine-5,7(1H,6H)-dione
-
linear uncompetitive mode of inhibition
1-((1-benzo[b]furan-2-yl)cyclohexyl)piperidine
-
-
1-((1-benzo[b]thiazol-2-yl)cyclohexyl)piperidine
-
-
1-((1-benzo[b]thiophen-2-yl)cyclohexyl)-4-methylpiperazine
-
-
1-((1-benzo[b]thiophen-2-yl)cyclohexyl)diethylamine
-
-
1-((1-benzo[b]thiophen-2-yl)cyclohexyl)pyrrolidine
-
-
1-((1-benzo[b]thiophen-2-yl)cyclopentyl)piperidine
-
-
1-((1-benzo[b]thiophen-3-yl)cyclohexyl)piperidine
-
-
1-((1-biphenyl-4-yl)cyclohexyl)piperidine
-
-
1-((1-naphthalen-1-yl)cyclohexyl)piperidine
-
-
1-((1-naphthalen-2-yl)cyclohexyl)piperidine
-
-
1-((1-thiophen-2-yl)cyclohexyl)piperidine
-
-
1-((2-(2,6-bis(phenylthio)phenyl)-1H-imidazol-5-yl)methyl)-4-methylpiperazine
1-((2-benzhydryloxy)ethyl)piperazine
-
-
1-((2-benzo[b]thiophen-2-yl)propan-2-yl)piperidine
-
-
1-(1-(3-bromo-benzo[b]thiophen-2-yl)cyclohexyl)piperidine
-
-
1-(1-(5-bromo-benzo[b]thiophen-2-yl)cyclohexyl)piperidine
-
-
1-(1-(benzo[b]thiophen-2-yl)cyclohexyl)-4-((1-(2,6-bis(phenylthio)phenyl)-1H-1,2,3-triazol-4-yl)methyl)piperazine
1-(1-(benzo[b]thiophen-2-yl)cyclohexyl)-4-((2-(2,6-bis(phenylthio)phenyl)-1H-imidazol-4-yl)methyl)piperazine
1-(1-(benzo[b]thiophen-2-yl)cyclohexyl)piperidine
1-(1-benzo[b]thiophen-2-yl-cyclohexyl)-piperidine
-
-
1-(1-benzo[b]thiophen-2-yl-cyclohexyl)piperidine
-
competitive inhibitor
1-(1-benzylpiperidin-4-yl)-3-phenylthiourea
-
-
1-(1-benzylpiperidin-4-yl)-3-pyridin-3-ylthiourea
-
-
1-(1-methylpiperidin-3-yl)-3-(2-phenoxyethyl)-1,3-dihydro-2H-benzimidazol-2-imine
-
IC50: 0.1 mM
1-(1-phenylcyclohexyl)piperidine
-
-
1-(1-phenylpiperidin-4-yl)-3-propylthiourea
-
-
1-(10-acetyl-10,10a-dihydro-4aH-phenothiazin-2-yl)-2-chloroethanone
-
-
1-(10-acetyl-10,10a-dihydro-4aH-phenothiazin-2-yl)ethanone
-
-
1-(10-acetyl-2-chloro-10,10a-dihydro-4aH-phenothiazin-8-yl)ethanone
-
-
1-(1H-indol-5-yl)-N-[(4-methylpiperazin-1-yl)methyl]methanediamine
-
0.1 mM, 31% or 39% inhibition in the presence of 0.11 mM or 0.04 mM trypanothione disulfide, respectively
1-(2,4-dichlorophenoxy)-3-[2-imino-3-(2-piperidin-1-ylethyl)-2,3-dihydro-1H-benzimidazol-1-yl]propan-2-ol
-
IC50: 0.005 mM
1-(2-(2,6-bis(phenylthio)phenyl)-1H-imidazol-5-yl)-N-((2-(2,6-bis(phenylthio)phenyl)-1H-imidazol-5-yl)methyl)-N,N-dimethylmethanaminium formate
1-(2-(2,6-bis(phenylthio)phenyl)-1H-imidazol-5-yl)-N-(3,4-dichlorobenzyl)-N,N-dimethylmethanaminium formate
1-(2-(benzhydryloxy)ethyl)-4-(3-phenylpropyl)piperazine
-
GBR-12935
1-(2-oxo-2-[[2-(phenylsulfanyl)phenyl]amino]ethyl)-4-phenylpiperazin-1-ium
1-(2-phenoxyethyl)-3-(2-piperidin-1-ylethyl)-1,3-dihydro-2H-benzimidazol-2-imine
-
IC50: 0.004 mM
1-(2-phenoxyethyl)-3-[2-(piperidin-1-yl)ethyl]-1,3-dihydro-2H-benzimidazol-2-imine
-
-
1-(3,4-dichlorobenzyl)-4-(2-[[2-[(7-methoxy-2-acridinyl)amino]-6-(phenylsulfanyl)benzyl]amino]-2-oxoethyl)-1-methylpiperazin-1-ium formate
1-(3,4-dichlorobenzyl)-4-[2-([2-[(7-methoxy-8a,10a-dihydroacridin-2-yl)amino]-6-(naphthalen-1-ylsulfanyl)benzyl]amino)-2-oxoethyl]-1-methylpiperazin-1-ium
1-(3,4-dichlorobenzyl)-4-[2-([2-[(7-methoxy-8a,10a-dihydroacridin-2-yl)amino]-6-(pyridin-2-ylsulfanyl)benzyl]amino)-2-oxoethyl]-1-methylpiperazin-1-ium
1-(3,4-dichlorophenyl)-2-[2-imino-3-(2-piperidin-1-ylethyl)-2,3-dihydro-1H-benzimidazol-1-yl]ethanol
1-(3,4-dichlorophenyl)-2-[3-[2-(diethylamino)ethyl]-2-imino-2,3-dihydro-1H-benzimidazol-1-yl]ethanol
-
IC50: 0.009 mM
1-(3,4-dichlorophenyl)-2-[3-[2-(diethylamino)ethyl]-2-imino-2,3-dihydro-1H-benzimidazol-1-yl]ethanone
-
IC50: 0.01 mM
1-(3,4-dichlorophenyl)-2-[3-[2-(dimethylamino)ethyl]-2-imino-2,3-dihydro-1H-benzimidazol-1-yl]ethanol
1-(3,4-dichlorophenyl)-3-(dimethylamino)propan-1-one
-
-
1-(3,4-dichlorophenyl)-3-[(4-ethylphenyl)amino]propan-1-one
-
containing two Cl groups and one NH-4-EtPh group
1-(3-bromobenzyl)-5,7-dimethyl-1,3-diazoniatricyclo[3.3.1.13,7]decane
1-(3-bromothiophen-2-yl)-N-(pyridin-3-ylmethyl)methanediamine
-
0.1 mM, 15% or 14% inhibition in the presence of 0.11 mM or 0.04 mM trypanothione disulfide, respectively
1-(3-nitrophenyl)-3-(phenylamino)propan-1-one
-
containing one NHPh group
1-(3-phenoxypropyl)-3-(2-piperidin-1-ylethyl)-1,3-dihydro-2H-benzimidazol-2-imine
-
IC50: 0.007 mM
1-(3-phenylpropyl)piperazine
-
-
1-(4'-(benzo[b]thiophen-2-yl)-1,4'-bipiperidinyl-1'-yl)-2-(dimethyl-amino)ethanone
-
-
1-(4'-(benzo[b]thiophen-2-yl)-1,4'-bipiperidinyl-1'-yl)-2-phenyl-ethanone
-
-
1-(4'-benzo[b]thiophen-2-yl)-1,4'-(bipiperidine-1'-yl)ethanone
-
-
1-(4,6,8-trimethylquinazolin-2-yl)guanidine
-
-
1-(4-bromophenyl)-2-(3-butyl-2-imino-2,3-dihydro-1H-benzimidazol-1-yl)ethanol
-
IC50: 0.1 mM, 42% inhibition at 0.025 mM
1-(4-chlorophenyl)-3-morpholin-4-ylpropan-1-one
-
containing one Cl group and one N-morpholinyl group
1-(4-ethoxyphenyl)-2-(2-imino-3-prop-2-en-1-yl-2,3-dihydro-1H-benzimidazol-1-yl)ethanol
-
IC50: 0.1 mM, 6% inhibition at 0.025 mM
1-(4-methylphenyl)-5-oxo-N-[2-(phenylsulfanyl)phenyl]pyrrolidine-3-carboxamide
1-(4-methylquinazolin-2-yl)guanidine
-
-
1-(4a,10a-dihydro-10H-phenothiazin-10-yl)-N,N,2-trimethylpropan-2-amine
-
-
1-(4a,10a-dihydro-10H-phenothiazin-10-yl)-N,N-dimethylpropan-2-amine
-
-
1-(5-phenoxypentyl)-3-(2-piperidin-1-ylethyl)-1,3-dihydro-2H-benzimidazol-2-imine
-
IC50: 0.008 mM
1-(8-chloro-10,11-dihydrodibenzo[b,f]thiepin-10-yl)-4-ethylpiperazinediium
1-(methylsulfanyl)-4-[3-(methylsulfanyl)-1,2,4-triazin-5-yl]-5,6,7,8-tetrahydroisoquinoline
-
-
1-([2-[5-bromo-2-(phenylsulfanyl)phenyl]-1H-imidazol-5-yl]methyl)-4-methylpiperazine
1-benzyl-4-[[(1E)-(1-cyclohexyl-2,4,6-trioxohexahydropyrimidin-5-yl)methylidene]amino]-1-methylpiperidinium
1-biphenyl-4-yl-2-[3-[2-(diethylamino)ethyl]-2-imino-2,3-dihydro-1H-benzimidazol-1-yl]ethanone
-
IC50: 0.025 mM
1-ethyl-6-methyl-3-(pyridin-3-yl)pyrimido[5,4-e][1,2,4]triazine-5,7(1H,6H)-dione
-
-
1-ethyl-6-methyl-3-(thiophen-2-yl)pyrimido[5,4-e][1,2,4]triazine-5,7(1H,6H)-dione
-
linear uncompetitive mode of inhibition
1-ethyl-6-methyl-3-phenylpyrimido[5,4-e][1,2,4]triazine-5,7(1H,6H)-dione
-
-
1-ethyl-6-methyl-3-[(Z)-2-phenylethenyl]pyrimido[5,4-e][1,2,4]triazine-5,7(1H,6H)-dione
-
-
1-ethyl-6-methyl-3-[4-(trifluoromethyl)phenyl]pyrimido[5,4-e][1,2,4]triazine-5,7(1H,6H)-dione
-
-
1-methyl-(2-(1-piperidin-1-yl)cyclohexyl)-1H-indole
-
-
1-phenyl-3-(1-phenylpiperidin-4-yl)thiourea
-
-
1-phenyl-3-[1-(pyridin-3-yl)piperidin-4-yl]urea
-
-
1-propylbenzene
-
-
1-[(4E)-5-(2-chlorophenyl)-3-oxopent-4-en-1-yl]piperidinium chloride
-
0.1 mM, irreversible inhibition
1-[1-(1-benzothiophen-2-yl)cyclohexyl]-4-([1-[5-bromo-2-(phenylsulfanyl)phenyl]-1H-1,2,3-triazol-4-yl]methyl)piperazine
1-[1-(1-benzothiophen-2-yl)cyclohexyl]-4-([2-[5-bromo-2-(phenylsulfanyl)phenyl]-1H-imidazol-4-yl]methyl)piperazine
1-[1-(1-benzothiophen-2-yl)cyclohexyl]piperidine
-
-
1-[2-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yloxy)ethyl]-4-(3-phenyl-propyl)piperazine
-
-
1-[2-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yloxy)ethyl]-4-(E)-(3-phenyl-allyl)piperazine
-
-
1-[2-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yloxy)ethyl]-piperazine
-
-
1-[2-(2-chloro-10H-phenothiazin-10-yl)-2-oxoethyl]azepanium
1-[2-(7-chloro-quinolin-4-ylamino)-ethyl]-1-[2-(N'',N''-dimethyl-aminomethyl)-ferrocenylmethyl]-3-p-chloro-phenyl-urea
1-[2-(7-chloro-quinolin-4-ylamino)-ethyl]-1-[2-(N'',N''-dimethyl-aminomethyl)ferrocenylmethyl]-3-[2,6-bis-(trifluoromethyl)-phenyl]-urea
-
ferrocenic 4-aminoquinoline urea compound 8
1-[2-(7-chloro-quinolin-4-ylamino)-ethyl]-1-[2-(N'',N''-dimethylaminomethyl)-ferrocenylmethyl]-3-p-methoxyphenyl-urea
1-[2-(7-chloro-quinolin-4-ylamino)-ethyl]-1-[2-(N'',N''-dimethylaminomethyl)-ferrocenylmethyl]-3-p-tolyl-urea
-
ferrocenic 4-aminoquinoline urea compound 5
1-[2-(7-chloro-quinolin-4-ylamino)-ethyl]-1-[2-(N'',N''-dimethylaminomethyl)-ferrocenylmethyl]-3-[2,4-bis-(trifluoromethyl)-phenyl]-urea
-
ferrocenic 4-aminoquinoline urea compound 7
1-[2-chloro-10-[3-(dimethylamino)propyl]-10,10a-dihydro-4aH-phenothiazin-8-yl]ethanone
-
-
1-[2-imino-3-(2-morpholin-4-ylethyl)-2,3-dihydro-1H-benzimidazol-1-yl]-3-phenoxypropan-2-ol
-
IC50: 0.1 mM
1-[2-imino-3-(2-piperidin-1-ylethyl)-2,3-dihydro-1H-benzimidazol-1-yl]-3,3-dimethylbutan-2-ol
-
IC50: 0.1 mM, 66% inhibition at 0.025 mM
1-[2-imino-3-(2-piperidin-1-ylethyl)-2,3-dihydro-1H-benzimidazol-1-yl]-3-(4-methoxyphenoxy)propan-2-ol
-
IC50: 0.016 mM
1-[2-imino-3-(2-piperidin-1-ylethyl)-2,3-dihydro-1H-benzimidazol-1-yl]-3-phenoxypropan-2-ol
-
IC50: 0.005 mM
1-[2-imino-3-(morpholin-4-ylethyl)-2,3-dihydro-1H-benzimidazol-1-yl]-3-(4-methylphenoxy)propan-2-ol
-
IC50: 0.1 mM
1-[2-imino-3-(piperidin-1-ylethyl)-2,3-dihydro-1H-benzimidazol-1-yl]-3-(4-methylphenoxy)propan-2-ol
-
IC50: 0.009 mM
1-[2-[2,6-bis(phenylsulfanyl)phenyl]-1H-imidazol-5-yl]-N,N-dimethylmethanamine
1-[4-(methylsulfonyl)phenyl]-3-piperidin-1-ylpropan-1-one
-
containing one N-piperidyl group
10-(bromoacetyl)-2-chloro-10,10a-dihydro-4aH-phenothiazine
-
-
10-butanoyl-2-chloro-10,10a-dihydro-4aH-phenothiazine
-
-
10-[3-(4-methylpiperidin-1-yl)propyl]-2-(trifluoromethyl)-10,10a-dihydro-4aH-phenothiazine
-
-
10H-phenothiazine
-
-
12-chloro-1,1-dimethyl-1,2,3,4,4a,13b-hexahydrodibenzo[2,3:6,7]thiepino[4,5-b]pyridin-1-ium
2,2'-(2-imino-1H-benzimidazole-1,3(2H)-diyl)bis(N,N-diethylethanamine)
-
IC50: 0.059 mM
2,2-dimethyl-2,3-dihydronaphtho[1,2-b]furan-4,5-dione
-
-
2,2-dimethyl-3,4-dihydro-2H-benzo[g]chromene-5,10-dione
-
-
2,2-dimethyl-3-(prop-2-en-1-yl)-3,4-dihydro-2H-benzo[h]chromene-5,6-dione
-
-
2,2-dimethyl-4a,10b-dihydro-2H-benzo[h]chromene-5,6-dione
-
-
2,3-Bis(3-(2-amidinohydrazono)-butyl)-1,4-naphthoquinone dihydrochloride
-
-
2,5-bis(3,4,5-trimethoxyphenyl)furan
-
3% inhibition at 0.02 mg/ml
2,5-bis(3,4-dimethoxyphenyl)furan
-
7% inhibition at 0.02 mg/ml
2,5-bis(4-methoxyphenyl)furan
-
15% inhibition at 0.02 mg/ml
2,5-bis(4-nitrophenyl)furan
-
9% inhibition at 0.02 mg/ml
2,5-bis[4-(trifluoromethyl)phenyl]furan
-
10% inhibition at 0.02 mg/ml
2,5-diphenylfuran
-
4% inhibition at 0.02 mg/ml
2-(1-cyclopentylcyclohexyl)-1-benzothiophene
2-(1-[3-[2-(trifluoromethyl)-4a,10a-dihydro-10H-phenothiazin-10-yl]propyl]piperidin-4-yl)ethanol
-
-
2-(2,4-dioxo-1,3-diazaspiro[4.6]undec-3-yl)-N-[2-(phenylsulfanyl)phenyl]acetamide
2-(2-chloro-4a,10a-dihydro-10H-phenothiazin-10-yl)-N,N-diethyl-2-oxoethanamine
-
-
2-(2-chloro-4a,10a-dihydro-10H-phenothiazin-10-yl)-N,N-diethylethanamine
-
-
2-(2-chloro-4a,10a-dihydro-10H-phenothiazin-10-yl)-N,N-dimethylethanamine
-
-
2-(3-benzyl-2-imino-2,3-dihydro-1H-benzimidazol-1-yl)-1-(4-chlorophenyl)ethanol
-
IC50: 0.1 mM, 32% inhibition at 0.025 mM
2-(4'-(benzo[b]thiophen-2-yl)-1,4'-bipiperidinyl-1'-yl)-N,N-dimethylethanamine
-
-
2-(4-nitrophenyl)furan
-
34% inhibition at 0.02 mg/ml
2-(4-[4-amino-6,7-bis[2-(dimethylamino)ethoxy]quinazolin-2-yl]piperazin-1-yl)naphthalene-1,4-dione
-
non-competitive inibition, 79% inhibition at 0.05 mM
2-(4a,10a-dihydro-10H-phenothiazin-10-yl)-N-methylethanamine
-
-
2-(5-methylfuran-2-yl)-N-(2-morpholinoethyl)quinoline-4-carboxamide
-
-
2-(5-methylfuran-2-yl)-N-(pyridin-2-ylmethyl)quinoline-4-carboxamide
-
-
2-(5-Nitro-2-furanylmethylidene)-N,N'-(1,4-piperazinediylbis(1,3-propanediyl))bishydrazinecarboximidamide tetrahydrobromide
-
-
-
2-(6-methyl-2,4-dioxo-1,3-diazaspiro[4.5]dec-3-yl)-N-[2-(phenylsulfanyl)phenyl]acetamide
2-(dimethylamino)-N-[2-[(7-methoxy-2-acridinyl)amino]-6-(phenylsulfanyl)benzyl]acetamide
2-(propan-2-yl)naphtho[1,2-b]furan-4,5-dione
-
-
2-(propan-2-yl)naphtho[2,3-b]furan-4,9-dione
-
-
2-([2-[(7-methoxy-8a,10a-dihydroacridin-2-yl)amino]-6-(naphthalen-1-ylsulfanyl)benzyl]amino)-N,N-dimethyl-N-[(5-nitrofuran-2-yl)methyl]-2-oxoethanaminium formate
2-([2-[(7-methoxy-8a,10a-dihydroacridin-2-yl)amino]-6-(pyridin-2-ylsulfanyl)benzyl]amino)-N,N-dimethyl-N-[(5-nitrofuran-2-yl)methyl]-2-oxoethanaminium formate
2-amino-4-chlorophenyl phenyl sulfide
-
weak inhibitor
2-chloro-10-(3-(4-(3-phenylpropyl)piperazin-1-yl)propyl)-10H-phenothiazine
-
-
2-chloro-10-(chloroacetyl)-10,10a-dihydro-4aH-phenothiazine
-
-
2-chloro-10-[3-[(Z)-propyldiazenyl]propyl]-10,10a-dihydro-4aH-phenothiazine
-
-
2-ethylnaphtho[2,3-b]furan-4,9-dione
-
-
2-hydroxy-3-(3-methylbut-2-en-1-yl)naphthalene-1,4-dione
-
-
2-hydroxy-3-[(1E)-3-methylbut-1-en-1-yl]naphthalene-1,4-dione
-
-
2-hydroxynaphthalene-1,4-dione
-
-
2-methoxy-6-chloro-9-aminoacridine/2-hydroxyethanethiolate (2,2':6',2''-terpyridine)platinum(II) complex
-
4 chimeric compound variants, competitive and irreversible inhibition, probably Cys52 of the enzyme is specifically modified, 4'-substituted (terpyridine)platinum(II) containing complexes do not inhibit irreversibly
2-methylnaphtho[2,3-b]furan-4,9-dione
-
-
2-nitronaphtho[2,3-b]thiophene-4,9-dione
-
-
2-propylnaphtho[1,2-b]furan-4,5-dione
-
-
2-[(1E)-but-1-en-1-yl]-3-hydroxynaphthalene-1,4-dione
-
-
2-[(4-bromophenyl)sulfanyl]-5-chloro-N-[3-(4-methylpiperazin-1-yl)propyl]aniline
2-[(E)-2-(4-nitrophenyl)ethenyl]-3-phenyl-5-(phenylamino)-2,5-dihydro-1,3,4-thiadiazol-3-ium chloride
2-[2-imino-3-(2-piperidin-1-ylethyl)-2,3-dihydro-1H-benzimidazol-1-yl]-1-(4-methoxyphenyl)ethanol
-
IC50: 0.024 mM, 85% inhibition at 0.025 mM
2-[3-(2-chloro-10H-phenothiazin-10-yl)-3-oxopropyl]octahydro-2H-pyrido[1,2-a]pyrazinediium
2-[3-[2-(diethylamino)ethyl]-2-imino-2,3-dihydro-1H-benzimidazol-1-yl]-1-(4-methoxyphenyl)ethanone
-
IC50: 0.007 mM, 91% inhibition at 0.025 mM
2-[3-[2-(diethylamino)ethyl]-2-imino-2,3-dihydro-1H-benzimidazol-1-yl]-1-(4-methylphenyl)ethanol
-
IC50: 0.019 mM
2-[3-[2-(dimethylamino)ethyl]-2-imino-2,3-dihydro-1H-benzimidazol-1-yl]-1-(4-methylphenyl)ethanol
-
IC50: 0.029 mM
2-[3-[2-(dimethylamino)propyl]-2-imino-2,3-dihydro-1H-benzimidazol-1-yl]-1-(4-methylphenyl)ethanol
-
IC50: 0.035 mM
2-[4-(1H-indol-3-ylacetyl)piperazin-1-yl]-6,7-dimethoxyquinazolin-4-amine
-
23% inhibition at 0.1 mM
2-[4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl]-5-methoxycyclohexa-2,5-diene-1,4-dione
-
non-competitive inibition, 75% inhibition at 0.1 mM
2-[4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl]naphthalene-1,4-dione
-
mixed-type inhibition, 57% inhibition at 0.1 mM
2-[5-[(4-methylpiperazin-1-yl)methyl]-1H-imidazol-2-yl]-N-phenyl-3-(phenylsulfanyl)aniline
2-[5-[(dimethylamino)methyl]-1H-imidazol-2-yl]-N-phenyl-3-(phenylsulfanyl)aniline
2-[[2-[(7-methoxy-2-acridinyl)amino]-6-(phenylsulfanyl)benzyl]amino]-N,N-dimethyl-N-(pentafluorobenzyl)-2-oxoethanaminium formate
2-[[2-[(7-methoxy-2-acridinyl)amino]-6-(phenylsulfanyl)benzyl]amino]-N,N-dimethyl-N-[(5-nitro-2-furyl)methyl]-2-oxoethanaminium formate
3',4'-dichlorobenzyl-[5-chloro-2-(phenylsulfanylphenylamino)-propyl]-dimethylammonium chloride
-
-
3,3'-[butane-1,4-diylbis[(3-aminopropyl)imino]]bis(N-[5-chloro-2-[(4-methoxyphenyl)sulfanyl]phenyl]propanamide)
-
IC50: 0.0003 mM
3,3'-[polyaminobis(carbonylalkyl)]bis(1,4-naphthoquinone) derivatives
-
-
-
3,4-dichloro-N-[3-(2-chloro-10H-phenothiazin-10-yl)propyl]-N,N-dimethylanilinium
-
-
3,4-dichloro-N-[3-([2-[(4-chlorophenyl)sulfanyl]phenyl]amino)propyl]-N,N-dimethylanilinium
-
-
3-((10H-phenothiazin-10-yl)methyl)-1-azoniabicyclo[2.2.2]octane
3-(11H-dibenzo[b,e][1,4]dithiepin-11-yl)-N,N-dimethylpropan-1-aminium
3-(11H-dibenzo[b,e][1,4]oxathiepin-11-ylmethyl)-1-methylpiperidinium
3-(2-acetyl-10H-phenothiazin-10-yl)-N,N-dimethylpropan-1-aminium
-
-
3-(2-butanoyl-10H-phenothiazin-10-yl)-N,N-dimethylpropan-1-aminium
-
-
3-(2-carbamoyl-10H-phenothiazin-10-yl)-N,N-dimethylpropan-1-aminium
-
-
3-(2-carboxy-10H-phenothiazin-10-yl)-N,N-dimethylpropan-1-aminium
-
-
3-(2-chloro-10H-phenothiazin-10-yl)-N,N-dimethyl-N-(4-methylbenzyl)propan-1-aminium
-
-
3-(2-chloro-10H-phenothiazin-10-yl)-N,N-dimethyl-N-(pentafluorobenzyl)propan-1-aminium
-
-
3-(2-chloro-10H-phenothiazin-10-yl)-N,N-dimethylpropan-1-amine
-
-
3-(2-chloro-10H-phenothiazin-10-yl)-N,N-dimethylpropan-1-aminium
-
-
3-(2-chloro-10H-phenothiazin-10-yl)-N-(3,4-dichlorobenzyl)-N,N-dimethylpropan-1-aminium
-
-
3-(2-chloro-10H-phenothiazin-10-yl)-N-(3,4-dimethylbenzyl)-N,N-dimethylpropan-1-aminium
-
-
3-(2-chloro-10H-phenothiazin-10-yl)-N-(3,5-dimethoxybenzyl)-N,N-dimethylpropan-1-aminium
-
-
3-(2-chloro-10H-phenothiazin-10-yl)-N-[4-(cyclohexylmethyl)benzyl]-N,N-dimethylpropan-1-aminium
-
-
3-(2-chloro-4a,10a-dihydro-10H-phenothiazin-10-yl)-N,N-diethyl-3-oxopropan-1-amine
-
-
3-(2-chloro-4a,10a-dihydro-10H-phenothiazin-10-yl)-N,N-diethylpropan-1-amine
-
-
3-(2-chloro-4a,10a-dihydro-10H-phenothiazin-10-yl)-N-methylpropan-1-amine
-
-
3-(2-chloro-4a,10a-dihydro-10H-phenothiazin-10-yl)propan-1-amine
-
-
3-(2-chloro-4a,10a-dihydro-10H-phenothiazin-10-yl)propanimidamide
-
-
3-(2-chloro-5-oxido-4a,10a-dihydro-10H-phenothiazin-10-yl)-N,N-dimethylpropan-1-amine
-
-
3-(2-hexanoyl-10H-phenothiazin-10-yl)-N,N-dimethylpropan-1-aminium
-
-
3-(3,4-dichlorophenyl)-N,N-dimethyl-3-oxopropan-1-aminium chloride
-
containing two Cl groups and one NMe2 HCl group
3-(4-chloro-4a,10a-dihydro-10H-phenothiazin-10-yl)-N,N-dimethylpropan-1-amine
-
-
3-(4a,10a-dihydro-10H-phenothiazin-10-yl)-N,N,2-trimethylpropan-1-amine
-
-
3-(4a,10a-dihydro-10H-phenothiazin-10-yl)propan-1-amine
-
-
3-(4a,10a-dihydro-10H-phenothiazin-10-yl)propanimidamide
-
-
3-(5-bromo-2-fluorophenyl)-1-butyl-6-methylpyrimido[5,4-e][1,2,4]triazine-5,7(1H,6H)-dione
-
-
3-(5-bromo-2-fluorophenyl)-1-cyclopentyl-6-methylpyrimido[5,4-e][1,2,4]triazine-5,7(1H,6H)-dione
-
-
3-(5-bromo-2-fluorophenyl)-1-ethyl-6-methylpyrimido[5,4-e][1,2,4]triazine-5,7(1H,6H)-dione
-
-
3-(5-bromo-2-fluorophenyl)-1-[2-(dimethylamino)ethyl]-6-methylpyrimido[5,4-e][1,2,4]triazine-5,7(1H,6H)-dione
-
-
3-(5-bromo-2-fluorophenyl)-6-methyl-1-(propan-2-yl)pyrimido[5,4-e][1,2,4]triazine-5,7(1H,6H)-dione
-
-
3-(5-bromo-2-fluorophenyl)-6-methylpyrimido[5,4-e,1,2,4]triazine-5,7(1H,6H)dione
-
-
3-(5-bromo-2-fluorophenyl)-6-methylpyrimido[5,4-e][1,2,4]triazine-5,7(1H,6H)-dione
-
-
3-(5-bromothiophen-2-yl)-1-ethyl-6-methylpyrimido[5,4-e][1,2,4]triazine-5,7(1H,6H)-dione
-
-
3-(dimethylamino)-1-(3-nitrophenyl)propan-1-one
-
-
3-(dimethylamino)-1-[4-(methylsulfonyl)phenyl]propan-1-one
-
-
3-(methylsulfanyl)-5-phenyl-1,2,4-triazine
-
-
3-([2-[(4-bromophenyl)sulfanyl]-5-chlorophenyl]amino)-N,N-dimethyl-N-[(5-nitrofuran-2-yl)methyl]propan-1-aminium bromide
3-([2-[(4-bromophenyl)sulfanyl]-5-chlorophenyl]amino)-N-(3,4-dichlorobenzyl)-N,N-dimethylpropan-1-aminium chloride
3-([2-[(4-tert-butylphenyl)amino]-5-fluorophenyl]amino)-N-(3,4-dichlorobenzyl)-N,N-dimethylpropan-1-aminium chloride
-
mixed-type inhibition
3-([5-chloro-2-[(4'-methylbiphenyl-4-yl)thio]phenyl]amino)-N-(3,4-dichlorobenzyl)-N,N-dimethylpropan-1-ammonium chloride
3-([5-chloro-2-[(4-chlorophenyl)sulfanyl]phenyl]amino)-N,N-dimethyl-N-[(5-nitrofuran-2-yl)methyl]propan-1-aminium bromide
3-([5-chloro-2-[(4-chlorophenyl)sulfanyl]phenyl]amino)-N-(3,4-dichlorobenzyl)-N,N-dimethylpropan-1-aminium chloride
3-([5-chloro-2-[1-naphthylthio]phenyl]amino)-N-(3,4-dichlorobenzyl)-N,N-dimethyl-propan-1-ammonium chloride
3-([5-chloro-2-[2-naphthylthio]phenyl]amino)-N-(3,4-dichlorobenzyl)-N,N-dimethyl-propan-1-ammonium chloride
3-acetylpyridine adenine nucleotide
-
-
3-benzyl-1-[2-(7-chloro-quinolin-4-ylamino)-ethyl]-1-[2-(N'',N''-dimethylaminomethyl)-ferrocenylmethyl]urea
3-Benzyl-1-[3-(7-chloro-quinolin-4-ylamino)-propyl]-1-[2-(N'',N''-dimethylaminomethyl)-ferrocenylmethyl]urea
-
-
3-Benzyl-1-[4-(7-chloro-quinolin-4-ylamino)-butyl]-1-[2-(N'',N''-dimethylaminomethyl)-ferrocenylmethyl]urea
-
-
3-Benzyl-1-[6-(7-chloro-quinolin-4-ylamino)-hexyl]-1-[2-(N'',N''-dimethylaminomethyl)-ferrocenylmethyl]urea
-
-
3-bromo-2,2-dimethyl-2H-benzo[g]chromene-5,10-dione
-
-
3-bromo-2,2-dimethyl-2H-benzo[h]chromene-5,6-dione
-
-
3-bromo-2,2-dimethyl-3,4-dihydro-2H-benzo[h]chromene-5,6-dione
-
-
3-Chloro-5-(3-(dimethylamino)propyl)-10,11-dihydro-5H-dibenz(b,f)azepine
3-cyano-1-azabicyclo[2.2.2]oct-3-yl acetate
-
-
3-methoxy-3'-(methylsulfanyl)-5,5'-bi-1,2,4-triazine
-
-
3-Phenylpropylamine
-
-
3-[(2,3-dimethylphenyl)amino]-1-(3-nitrophenyl)propan-1-one
-
containing one NH-2,3-diMePh group
3-[(3-fluorophenyl)amino]-1-(3-nitrophenyl)propan-1-one
-
containing one NH-3-FPh group
3-[(5-chloro-2-[[2-(trifluoromethyl)phenyl]thio]phenyl)amino]-N-(3,4-dichlorobenzyl)-N,N-dimethylpropan-1-ammonium chloride
3-[(5-chloro-2-[[3-(trifluoromethyl)phenyl]thio]phenyl)amino]-N-(3,4-dichlorobenzyl)-N,N-dimethylpropan-1-ammonium chloride
3-[(5-chloro-2-[[4-(trifluoromethyl)phenyl]sulfanyl]phenyl)amino]-N,N-dimethyl-N-[(5-nitrofuran-2-yl)methyl]propan-1-aminium bromide
3-[(5-chloro-2-[[4-(trifluoromethyl)phenyl]sulfanyl]phenyl)amino]-N-(3,4-dichlorobenzyl)-N,N-dimethylpropan-1-aminium chloride
3-[2-(aminomethyl)-10H-phenothiazin-10-yl]-N,N-dimethylpropan-1-aminium
-
-
3-[2-(hydroxymethyl)-10H-phenothiazin-10-yl]-N,N-dimethylpropan-1-aminium
-
-
3-[2-(methoxycarbonyl)-10H-phenothiazin-10-yl]-N,N-dimethylpropan-1-aminium
-
-
3-[2-[(1E)-N-benzyl-N-oxidoethanimidoyl]-10H-phenothiazin-10-yl]-N,N-dimethylpropan-1-aminium
-
-
3-[2-[(E)-(hydroxyimino)methyl]-10H-phenothiazin-10-yl]-N,N-dimethylpropan-1-aminium
-
-
3-[[5-chloro-2-(phenylsulfanyl)phenyl]amino]-N,N-dimethyl-N-[(5-nitrofuran-2-yl)methyl]propan-1-aminium bromide
3-[[5-chloro-2-(phenylsulfanyl)phenyl]amino]-N-(3,4-dichlorobenzyl)-N,N-dimethylpropan-1-aminium chloride
3-[[5-chloro-2-(phenylsulfanyl)phenyl]amino]-N-(3,4-dichlorobenzyl)-N,N-dimethylpropan-1-ammonium chloride
4'-(benzo[b]thiophen-2-yl)-1'-benzyl-1,4'-bipiperidine
-
-
4'-(benzo[b]thiophen-2-yl)-1'-methyl-1,4'-bipiperidine
-
-
4'-(benzo[b]thiophen-2-yl)-[1,4']bipiperidine
-
-
4,4'-bis(4-benzyloxy-3-methoxybenzimidoylamino)di-cyclohexylmethane
-
97% inhibition at 0.1 mM, in the presence of 0.1 mM trypanothione disulfide
4,4'-furan-2,5-diyldibenzonitrile
-
11% inhibition at 0.02 mg/ml
4,6,8-trimethyl-N-(4,4,6-trimethyl-1,4-dihydropyrimidin-2-yl)quinazolin-2-amine
-
-
4-((1-(4-ethylphenyl)-2-methyl-5-(4-(methylthio)phenyl)-1H-pyrrol-3-yl)methyl)thiomorpholine
-
most active inhibitor
4-(2-(4'-(benzo[b]thiophen-2-yl)-1,4'-bipiperidin-1'-yl)ethyl)morpholine
-
-
4-(2-chloro-4a,10a-dihydro-10H-phenothiazin-10-yl)-4-oxo-N'-phenylbutanehydrazide
-
-
4-(2-chloro-4a,10a-dihydro-10H-phenothiazin-10-yl)-4-oxobutanoic acid
-
-
4-(2-chloro-4a,10a-dihydro-10H-phenothiazin-10-yl)-N,N-diethyl-4-oxobutan-1-amine
-
-
4-(2-chlorobenzyl)cyclopent-2-en-1-one
-
0.1 mM, reversible inhibition
4-(2-[[2-[(7-methoxy-2-acridinyl)amino]-6-(phenylsulfanyl)benzyl]amino]-2-oxoethyl)-1-methyl-1-(pentafluorobenzyl)piperazin-1-ium formate
4-(azepan-1-ylmethyl)-2,6-di-tert-butylphenol
-
containing one Bu group and one N-homopiperidylde group
4-(benzofuroxan-5-ylmethyloxy)benzaldehyde amidinohydrazone
-
50% of inhibition at a inhibitor dose of 0.1 mM, 30% of inhibition at a inhibitor dose of 0.04 mM
4-(benzyloxy)-N-[3-([2-[(4-chlorophenyl)sulfanyl]phenyl]amino)propyl]-N,N-dimethylanilinium
-
-
4-chloromercuribenzoic acid
-
-
4-furan-2-ylbenzenesulfonamide
-
8% inhibition at 0.02 mg/ml
4-furan-2-ylbenzonitrile
-
5% inhibition at 0.02 mg/ml
4-[(4E)-5-(2-chlorophenyl)-3-oxopent-4-en-1-yl]morpholin-4-ium chloride
-
0.1 mM, irreversible inhibition
4-[(7-chloro-4-nitro-2,1,3-benzothiadiazol-5-yl)sulfanyl]quinazoline
-
reversible. Compound inhibits parasite proliferation with EC50 values between 50 and 5 microM
4-[(dimethylamino)methyl]-2,6-bis(1-methylethyl)phenol
-
containing one Pr group and one NMe2 group
4-[1-(1-benzothiophen-2-yl)cyclohexyl]morpholine
-
-
4-[2-([2-[(7-methoxy-8a,10a-dihydroacridin-2-yl)amino]-6-(naphthalen-1-ylsulfanyl)benzyl]amino)-2-oxoethyl]-1-methyl-1-[(5-nitrofuran-2-yl)methyl]piperazin-1-ium formate
4-[2-([2-[(7-methoxy-8a,10a-dihydroacridin-2-yl)amino]-6-(pyridin-2-ylsulfanyl)benzyl]amino)-2-oxoethyl]-1-methyl-1-[(5-nitrofuran-2-yl)methyl]piperazin-1-ium formate
4-[6-[(3-chlorophenyl)carbamoyl]-4-oxo-1,4,5,6-tetrahydropyrimidin-2-yl]-1-methylpiperazin-1-ium
4-[[bis(2-hydroxyethyl)amino]methyl]-2,6-dibutylphenol
-
-
5,5'-dithiobis(N-[3-(4-methylpiperazin-1-yl)propyl]-2-nitrobenzamide)
-
recombinant enzyme
5,6-dimethyl-2-[(4,6,8-trimethylquinazolin-2-yl)amino]pyrimidin-4-ol
-
-
5,7-dichloro-4-nitro-2,1,3-benzothiadiazole
-
reversible. Compound inhibits parasite proliferation with EC50 values between 50 and 5 microM
5,7-dimethoxynaphtho[2,3-b]thiophene-4,9-dione
-
-
5-(2-chloroethoxy)-10,11-dihydro-5H-dibenzo[a,d]cycloheptene
-
-
5-chloro-2-[(4-chlorophenyl)sulfanyl]-N-[3-(4-methylpiperazin-1-yl)propyl]aniline
5-chloro-N-[3-(4-methylpiperazin-1-yl)propyl]-2-(phenylsulfanyl)aniline
5-chloro-N-[3-(4-methylpiperazin-1-yl)propyl]-2-[(2-naphthalen-1-ylphenyl)sulfanyl]aniline
5-chloro-N-[3-(4-methylpiperazin-1-yl)propyl]-2-[(2-naphthalen-2-ylphenyl)sulfanyl]aniline
5-chloro-N-[3-(4-methylpiperazin-1-yl)propyl]-2-[(2-pyridin-2-ylphenyl)sulfanyl]aniline
-
-
5-chloro-N-[3-(4-methylpiperazin-1-yl)propyl]-2-[[2-(trifluoromethyl)phenyl]sulfanyl]aniline
5-chloro-N-[3-(4-methylpiperazin-1-yl)propyl]-2-[[3-(trifluoromethyl)phenyl]sulfanyl]aniline
5-chloro-N-[3-(4-methylpiperazin-1-yl)propyl]-2-[[4-(trifluoromethyl)phenyl]sulfanyl]aniline
5-methoxynaphtho[2,3-b]furan-4,9-dione
-
-
5-nitro-furan-2-carboxylic acid (3-dimethylamino-propyl)-amide
reversible uncompetitive inhibition regarding substrate trypanothione disulfide, IC50 value for Trypanooma cruzi growth inhibition 0.0019 microM, EC50 value for toxicity against HeLa cells 0.074 microM
5-nitro-furan-2-carboxylic acid benzylamide amide
reversible uncompetitive inhibition regarding substrate trypanothione disulfide, IC50 value for Trypanooma cruzi growth inhibition 0.0015 microM, EC50 value for toxicity against HeLa cells 0.123 microM
-
5-nitro-furan-2-carboxylic acid dibenzylamide amide
reversible uncompetitive inhibition regarding substrate trypanothione disulfide, IC50 value for Trypanooma cruzi growth inhibition 0.0001 microM, EC50 value for toxicity against HeLa cells 0.078 microM
-
5-nitrofuran-2-carbaldehyde N-butylsemicarbazone
-
-
6,7-bis[2-(dimethylamino)ethoxy]-2-[4-(1H-indol-3-ylacetyl)piperazin-1-yl]quinazolin-4-amine
-
44% inhibition at 0.05 mM
6,7-dimethoxy-2-[4-[(3R)-1,2,3,4-tetrahydroisoquinolin-3-ylcarbonyl]piperazin-1-yl]quinazolin-4-amine
-
complete inhibition at 0.1 mM
6,7-dimethoxy-2-[4-[(3S)-1,2,3,4-tetrahydroisoquinolin-3-ylcarbonyl]piperazin-1-yl]quinazolin-4-amine
-
complete inhibition at 0.1 mM
6-(2-chloro-4a,10a-dihydro-10H-phenothiazin-10-yl)-N,N-diethyl-6-oxohexan-1-amine
-
-
6-(naphthalen-2-ylamino)-6-oxohexane-1,5-diaminium
6-(sec-butoxy)-2-((3-chlorophenyl)thio)pyrimidin-4-amine
-
i.e. RD 777. IC50 value 0.029 microM for promastigote assay. Competitive with respect to substrate trypanothione disulfide
6-bromo-2-(5-methylfuran-2-yl)-N-(2-morpholinoethyl)quinoline-4-carboxamide
-
linear mixed-type inhibition
6-bromo-2-(5-methylfuran-2-yl)-N-(4-sulfamoylbenzyl)quinoline-4-carboxamide
-
-
6-bromo-2-(5-methylfuran-2-yl)-N-(morpholin-4-yl)quinoline-4-carboxamide
-
-
6-bromo-2-(5-methylfuran-2-yl)-N-(pyridin-2-ylmethyl)quinoline-4-carboxamide
-
linear mixed-type inhibition
6-bromo-2-(5-methylfuran-2-yl)-N-(pyridin-3-yl)quinoline-4-carboxamide
-
-
6-bromo-2-(5-methylfuran-2-yl)-N-phenethylquinoline-4-carboxamide
-
-
6-bromo-N,N,N-trimethyl-2-(2-(5-methylfuran-2-yl)quinoline-4-carboxamido)ethanaminium iodide
-
-
6-bromo-N-(2-(dimethylamino)ethyl)-2-(5-methylfuran-2-yl)quinoline-4-carboxamide
-
linear mixed-type inhibition
6-bromo-N-(2-(dimethylamino)ethyl)-2-(5-methylthiophen-2-yl)-quinoline-4-carboxamide
-
-
6-bromo-N-(2-(dimethylamino)ethyl)-2-(furan-2-yl)quinoline-4-carboxamide
-
-
6-bromo-N-(2-(methylamino)ethyl)-2-(5-methylfuran-2-yl)quinoline-4-carboxamide
-
-
6-bromo-N-(furan-2-ylmethyl)-2-(5-methylfuran-2-yl)quinoline-4-carboxamide
-
-
6-bromo-N-[2-(dimethylamino)ethyl]-2-(pyridin-4-yl)quinoline-4-carboxamide
-
-
6-bromo-N-[2-(dimethylamino)ethyl]-2-phenylquinoline-4-carboxamide
-
-
6-bromo-N-[3-(1H-imidazol-1-ylamino)propyl]-2-(5-methylfuran-2-yl)quinoline-4-carboxamide
-
-
6-chloro-2-(5-methylfuran-2-yl)-N-[3-(morpholin-4-yl)propyl]quinoline-4-carboxamide
-
-
6-chloro-2-methoxyacridin-9-amine
-
-
6-chloro-3-[3-(3-hydroxy-2-piperidyl)-2-oxo-propyl]-7-(4-pyridyl) quinazolin-4-one
-
febrifugine analogue, putative inhibitor identified by molecular docking
-
6-chloro-N-(2-(dimethylamino)ethyl)-2-(5-methylfuran-2-yl)quinoline-4-carboxamide
-
-
6-chloro-N-[2-(dimethylamino)ethyl]-3-methyl-2-(4-methylphenyl)quinoline-4-carboxamide
-
-
6-chlorotacrine
-
competitive inhibition
6-methoxynaphtho[2,3-b]furan-4,9-dione
-
-
7,8-dimethoxynaphtho[2,3-b]thiophene-4,9-dione
-
-
7-bromo-N-(2-(dimethylamino)ethyl)-2-(5-methylfuran-2-yl)quinoline-4-carboxamide
-
-
7-ethoxy-4-methyl-N-(4,4,6-trimethyl-4,5-dihydropyrimidin-2-yl)quinazolin-2-amine
-
-
7-ethyl-4-methyl-N-(4,4,6-trimethyl-4,5-dihydropyrimidin-2-yl)quinazolin-2-amine
-
-
7-methoxy-N-[2-([[2-(4-methylpiperazin-1-yl)ethyl]amino]methyl)-3-[[4-(trifluoromethyl)phenyl]sulfanyl]phenyl]-4a,9a-dihydroacridin-2-amine
8-bromo-N-(2-(dimethylamino)ethyl)-2-(5-methylfuran-2-yl)quinoline-4-carboxamide
-
-
8-methoxynaphtho[2,3-b]furan-4,9-dione
-
-
9-Amino-1,2,3,4-tetrahydroacridine
-
i.e. tacrine, competitive inhibition
9-aminoacridine derivatives
-
competitive inhibition
9-hydroxy-2,2-dimethyl-3,4-dihydro-2H-benzo[h]chromene-5,6-dione
-
-
9-thioacridine derivatives
-
mixed-type inhibition
Ac-PAIIQSVGISNLKNL-NH2
-
about 30% residual activity at 0.025 mM
Ac-PEIIQSVGISMKM-NH2
-
-
Ac-PEIIQSVGISNLKNL-NH2
-
-
Ac-PKAIQSVGISNLKNL-NH2
-
about 18% residual activity at 0.025 mM
Ac-PKIIASVGISNLKNL-NH2
-
about 65% residual activity at 0.025 mM
Ac-PKIIQAVGISNLKNL-NH2
-
about 10% residual activity at 0.025 mM
Ac-PKIIQSAGISNLKNL-NH2
-
about 19% residual activity at 0.025 mM
Ac-PKIIQSVAISNLKNL-NH2
-
about 20% residual activity at 0.025 mM
Ac-PKIIQSVGASNLKNL-NH2
-
about 22% residual activity at 0.025 mM
Ac-PKIIQSVGIANLKNL-NH2
-
about 15% residual activity at 0.025 mM
Ac-PKIIQSVGISAKNL-NH2
-
about 30% residual activity at 0.025 mM
Ac-PKIIQSVGISMKM-NH2
-
the enzyme is almost completely inactivated after 50 min (3000 s) in the presence of 0.025 mM
Ac-PKIIQSVGISNLANL-NH2
-
about 31% residual activity at 0.025 mM
Ac-PKIIQSVGISNLKA-NH2
-
about 31% residual activity at 0.025 mM
Ac-PKIIQSVGISNLKNL-NH2
-
about 20% residual activity at 0.025 mM
acylspermines and acylspermidines
-
-
ajoene
altenusin
alternariol
-
no inhibitory activity
alternariol methyl ether
-
no inhibitory activity
amitryptyline
Amphotericin B
-
0.0346 mM, 100% inhibition
antimony chloride
-
assay containing 10% vol. methanol
arsenite
-
+ NADPH, slightly
aspidospermine
Au(2-(2'-pyridyl)benzimidazole)Cl2
-
-
-
Au-(N-(1-hydroxy-3-methylbutan-2-yl)pyridine-2-carboxamide)Cl
-
-
-
auranofin
-
-
Bay 11-7085
-
-
benznidazole
-
growth inhibition
benzofuroxan-5-carboxaldehyde thiosemicarbazone
-
19% of inhibition at a inhibitor dose of 0.1 mM, 9% of inhibition at a inhibitor dose of 0.04 mM
benzoyl-Gly-L-Arg-L-Arg-L-Leu-beta-naphthylamide
-
reversible and competitive inhibition
benzoyl-L-Arg-p-nitroanilide
-
reversible and competitive inhibition
benzoyl-L-Leu-L-Arg-L-Arg-beta-naphthylamide
-
reversible and competitive inhibition
benzoyl-L-Phe-L-Val-L-Arg-7-amido-4-methylcoumarin
-
reversible and competitive inhibition
benzoyl-Lys-Phe-Arg-p-nitroanilide
-
reversible and competitive inhibition
benzo[b]thiophen-2-yl(1-(piperidin-1-yl)cyclohexyl)methanone
-
-
benzyloxycarbonyl-Ala-Arg-Arg-4-methoxy-beta-naphthylamide
-
reversible and competitive inhibition
benzyloxycarbonyl-Gly-Gly-L-Arg-7-amido-4-methylcoumarin
-
reversible and competitive inhibition
benzyloxycarbonyl-L-Arg-L-Arg-4-methoxy-beta-naphthylamide
-
reversible and competitive inhibition
benzyloxycarbonyl-L-Arg-L-Arg-p-nitroanilide
-
reversible and competitive inhibition
benzyloxycarbonyl-L-Arg-p-nitroanilide
-
reversible and competitive inhibition
benzyloxycarbonyl-L-Lys-4-methoxy-beta-naphthylamide
-
reversible and competitive inhibition
bis(9H-fluoren-9-ylmethyl) [(18S,23S)-3,14,17,24-tetraoxo-1,4,8,13,16-pentaazacyclotetracosane-18,23-diyl]biscarbamate
-
lack the disulfide and trypanothione's gamma-glutamyl groups have been replaced by hydrophobic aromatic moieties
bis(tetrahydrocinnamoyl)spermine
-
i.e. kukoamine A
bisbenzylisoquinoline alkaloids
-
e.g. cepharanthine, (-)curine, daphnoline, antioquine, limacine, cycleanine
-
bromoacetyl alprenolol menthane
-
-
butyl 4-[[3-(3-nitrophenyl)-3-oxopropyl]amino]benzoate
-
containing one NH-4-(CO2-nBu)Ph group
carmustine
-
-
cephalotaxine
-
compound is an alkaloid scaffold lead in the search for inhibitors
-
cepharanthine
-
-
chinifur
Chloroquine
-
-
chlorpromazine
chlorpromazoine
-
-
cis-3-(1,3-dioxolan-2-yl)-8-bromo-9b-(trans-acrylic acid)-1,2,3,4,4a,9b-hexahydrodibenzofuran
Lunaria biennis
-
0.1 mM
cis-3-oxo-8,9b-bis-(trans-N-(acrylamidospermidyl))-1,2,3,4,4a,9b-hexahydrodibenzofuran
Lunaria biennis
-
IC50: 0.029 mM
cis-3-oxo-8,9b-bis-(trans-N3-(dimethylamino)propylacrylamido)-1,2,3,4,4a,9b-hexahydrodibenzofuran
Lunaria biennis
-
0.1 mM
cis-3-oxo-8-trans-(N-acrylamidospermidyl)-9b-trans-ethylacrylyl-1,2,3,4,4a,9b-hexahydrodibenzofuran
Lunaria biennis
-
IC50: 0.056 mM
cis-3-oxo-8-trans-(N1-acrylamidospermidyl)-9b-trans-ethylacrylyl-1,2,3,4,4a,9b-hexahydrodibenzofuran
Lunaria biennis
-
-
citalopram
-
-
clomipramine
connesine
-
97% growth inhibition
crude extract of Lentinus strigosus
-
100% inhibition of trypanothione reductase
-
cryptolepine
-
compound is an alkaloid scaffold lead in the search for inhibitors
-
cycleanine
-
-
cymelarsen
-
+ NADPH
dethiotrypanothione
-
trypanothione disulfide analogue 2, lack the disulfide
dibenzyl [(18S,23S)-3,14,17,24-tetraoxo-1,4,8,13,16-pentaazacyclotetracosane-18,23-diyl]biscarbamate
-
lack the disulfide and trypanothione's gamma-glutamyl groups have been replaced by hydrophobic aromatic moieties
dihydrohypnophilin
-
no inhibitory activity
diphenyl(1-(piperidin-1-yl)cyclohexyl)methanol
-
-
ethyl 2-acetyl-5-[4-butyl-2-(3-hydroxypentyl)-5-nitro-1H-imidazol-1-yl]pent-2-enoate
-
putative drug candidate for the treatment of visceral leishmaniasis
-
eupomatenoid-5
-
eupomatenoid-5 decreases enzyme activity, leading to a relative increase in reactive oxygen species that triggers mitochondrial depolarization followed by an absolute increase in mitochondrial reactive oxygen and nitrogen species production through the electron transport chain. This increase in reactive oxygen and nitro-gen species induces oxidative damage, leading to parasite death
formate
Gentian violet
-
wild-type and recombinant enzyme overexpressing cells
H2O2
-
wild-type and recombinant enzyme overexpressing cells
heptyl (2E)-2-[(2E)-3-(5-nitrofuran-2-yl)prop-2-en-1-ylidene]hydrazinecarboxylate
-
-
hexyl (2E)-2-[(5-nitrofuran-2-yl)methylidene]hydrazinecarboxylate
-
-
hypnophilin
-
100% inhibition of trypanothione reductase, reduces the proliferation of human peripheral blood monocluear cells, not cytotoxic for lymphocytes and monocytes
iodoacetamide
isopropyl 2-isobutyryl-3-trifluoromethylquinoxaline-7-carboxylate 1,4-di-N-oxide
-
noncompetitive. IC50 values against strains NINOA and INC-5 are 0.060 microM and 0.073 microM, respectively, IC50 against human glutathione reductase is 0.050 microM
juglone
juglone derivatives
kukoamine A
-
mixed inhibitor
K[Au(saccharine)2]
-
-
K[Au(saccharine)4]
-
-
L-Arg-beta-naphthylamide
-
reversible and competitive inhibition
L-His-L-Trp-L-His
-
reversible and competitive inhibition
L-His-L-Trp-L-Lys
-
reversible and competitive inhibition
L-Phe-L-Arg-L-Trp
-
reversible and competitive inhibition
L-Phe-L-Met-L-Arg-L-Phe-NH2
-
reversible and competitive inhibition
L-Phe-L-Pro-L-Arg-4-methoxy-beta-naphthylamide
-
reversible and competitive inhibition
L-Trp
-
reversible and competitive inhibition
L-Trp-beta-naphthylamide
-
reversible and competitive inhibition
lunarine
lunarinol
Lunaria biennis
-
0.1 mM
Melarsen oxide
melarsen-trypanothione disulfide adduct
melarsen-trypanothione disulfide-adduct
melarsoprol
-
+ NADPH, slightly
MelT
-
adduct of melarsen oxide with dihydrotrypanothione
menadione derivatives
-
Mepacrine
miconazole
-
0.064 mM, 100% inhibition
N'-(2-[(7-methoxy-4a,9a-dihydroacridin-2-yl)amino]-6-[[4-(trifluoromethyl)phenyl]sulfanyl]benzyl)-N,N-dimethylethane-1,2-diamine
N'-(5-chloro-2-[[2-(trifluoromethyl)phenyl]sulfanyl]phenyl)-N,N-dimethylpropane-1,3-diamine
N'-(5-chloro-2-[[3-(trifluoromethyl)phenyl]sulfanyl]phenyl)-N,N-dimethylpropane-1,3-diamine
-
-
N'-(5-chloro-2-[[4-(trifluoromethyl)phenyl]sulfanyl]phenyl)-N,N-dimethylpropane-1,3-diamine
N'-[2-[(4-bromophenyl)sulfanyl]-5-chlorophenyl]-N,N-dimethylpropane-1,3-diamine
N'-[2-[(7-methoxy-2-acridinyl)amino]-6-(phenylsulfanyl)benzyl]-N,N-dimethyl-1,2-ethanediamine
N'-[2-[(7-methoxy-4a,9a-dihydroacridin-2-yl)amino]-6-(pyridin-2-ylsulfanyl)benzyl]-N,N-dimethylethane-1,2-diamine
N'-[5-chloro-2-(naphthalen-1-ylsulfanyl)phenyl]-N,N-dimethylpropane-1,3-diamine
N'-[5-chloro-2-(naphthalen-2-ylsulfanyl)phenyl]-N,N-dimethylpropane-1,3-diamine
N'-[5-chloro-2-(phenylsulfanyl)phenyl]-N,N-dimethylpropane-1,3-diamine
N'-[5-chloro-2-[(4-chlorophenyl)sulfanyl]phenyl]-N,N-dimethylpropane-1,3-diamine
N,N'-(furan-2,5-diyldibenzene-4,1-diyl)diacetamide
-
IC50: 0.0485 mM, 54% inhibition at 0.02 mg/ml
N,N-diethyl-2-(2-imino-3-prop-2-en-1-yl-2,3-dihydro-1H-benzimidazol-1-yl)ethanamine
-
IC50: 0.1 mM, 31% inhibition at 0.025 mM
N,N-diethyl-2-[2-imino-3-(2-phenoxyethyl)-2,3-dihydro-1H-benzimidazol-1-yl]ethanamine
-
IC50: 0.008 mM
N,N-dimethyl-3-(10H-phenothiazin-10-yl)propan-1-aminium
-
-
N,N-dimethyl-3-(2-propanoyl-10H-phenothiazin-10-yl)propan-1-aminium
-
-
N,N-dimethyl-3-(3-nitrophenyl)-3-oxopropan-1-aminium chloride
-
containing one NMe2 HCl group
N,N-dimethyl-3-[2-(trifluoromethyl)-10H-phenothiazin-10-yl]propan-1-aminium
-
-
N,N-dimethyl-3-[2-[(1E)-N-methyl-N-oxidoethanimidoyl]-10H-phenothiazin-10-yl]propan-1-aminium
-
-
N,N-dimethyl-3-[4-(methylsulfonyl)phenyl]-3-oxopropan-1-aminium chloride
-
containing one NMe2 HCl group
N,N-dimethyl-N-[3-(7-methoxy-1-methyl-3,4-dihydro-9H-beta-carbolin-9-yl)propyl]amine
N-(2-(dimethylamino)ethyl)-2-(5-methylfuran-2-yl)quinoline-4-carboxamide
-
-
N-(2-(dimethylamino)ethyl)-6-fluoro-2-(5-methylfuran-2-yl)quinoline-4-carboxamide
-
-
N-(2-phenoxyethyl)-N'-(2-piperidin-1-ylethyl)benzene-1,2-diamine
-
IC50: 0.1 mM
N-(2-[(7-methoxy-4a,9a-dihydroacridin-2-yl)amino]-6-[[4-(trifluoromethyl)phenyl]sulfanyl]benzyl)-2-(4-methylpiperazin-1-yl)acetamide
N-(2-[(7-methoxy-4a,9a-dihydroacridin-2-yl)amino]-6-[[4-(trifluoromethyl)phenyl]sulfanyl]benzyl)-N2,N2-dimethylglycinamide
N-(3,4-dichlorobenzyl)-2-([2-[(7-methoxy-8a,10a-dihydroacridin-2-yl)amino]-6-(naphthalen-1-ylsulfanyl)benzyl]amino)-N,N-dimethyl-2-oxoethanaminium
N-(3,4-dichlorobenzyl)-2-([2-[(7-methoxy-8a,10a-dihydroacridin-2-yl)amino]-6-(pyridin-2-ylsulfanyl)benzyl]amino)-N,N-dimethyl-2-oxoethanaminium
N-(3,4-dichlorobenzyl)-2-[[2-[(7-methoxy-2-acridinyl)amino]-6-(phenylsulfanyl)benzyl]amino]-N,N-dimethyl-2-oxoethanaminium
N-(3,4-dichlorobenzyl)-3-[(5-fluoro-2-[[4-(pentafluoro-l6-sulfanyl)phenyl]amino]phenyl)amino]-N,N-dimethylpropan-1-aminium chloride
-
mixed-type inhibition
N-(3,4-dichlorobenzyl)-3-[(5-fluoro-2-[[4-(trifluoromethyl)phenyl]amino]phenyl)amino]-N,N-dimethylpropan-1-aminium chloride
-
competitive inhibition
N-(3,5-di-tert-butyl-4-hydroxybenzyl)-2-hydroxyethanaminium chloride
-
containing one Bu group and one N((CH2)2OH) HCl group
N-(3-chlorobenzyl)-3-(2-chloro-10H-phenothiazin-10-yl)-N,N-dimethylpropan-1-aminium
-
-
N-(3-chlorophenyl)-N',N'-dimethyl-N-phenylpropane-1,3-diamine
-
-
N-(3-dimethylamino-propyl)-O-[(E)-3-(3-[(E)-3-[N-(3-dimethylamino-propyl)aminooxy]-propenyl]-benzofuran-5-yl)-allyl]-hydroxylamine
-
benzofuranyl-based acyclic bis-polyamine analogue of lunarine with a planar bicyclic benzofuranyl scaffold, inhibition mechanism
N-(4,6-dimethylpyrimidin-2-yl)-4,5,7-trimethylquinazolin-2-amine
-
-
N-(4,6-dimethylpyrimidin-2-yl)-4,6-dimethylquinazolin-2-amine
-
-
N-(4-bromobenzyl)-3-(2-chloro-10H-phenothiazin-10-yl)-N,N-dimethylpropan-1-aminium
-
-
N-(4-chlorobenzyl)-3-(2-chloro-10H-phenothiazin-10-yl)-N,N-dimethylpropan-1-aminium
-
-
N-(4-tert-butylbenzyl)-3-(2-chloro-10H-phenothiazin-10-yl)-N,N-dimethylpropan-1-aminium
-
-
N-(7-Chloro-quinolin-4-yl)-N'-[2-(N'',N''-dimethyl-aminomethyl)ferrocenylmethyl]-butane-1,4-diamine
-
-
N-(7-Chloro-quinolin-4-yl)-N'-[2-(N'',N''-dimethyl-aminomethyl)ferrocenylmethyl]-ethane-1,2-diamine
-
enzyme and growth inhibition
N-(7-Chloro-quinolin-4-yl)-N'-[2-(N'',N''-dimethyl-aminomethyl)ferrocenylmethyl]-hexane-1,6-diamine
-
-
N-(7-Chloro-quinolin-4-yl)-N'-[2-(N'',N''-dimethyl-aminomethyl)ferrocenylmethyl]-propane-1,3-diamine
-
-
N-(7-Chloro-quinolin-4-yl)-N'-[2-(N'',N''-dimethylaminomethyl)ferrocenylmethyl]-ethane-1,2-diamine
N-(pyridin-3-ylmethyl)-1-thiophen-2-ylmethanediamine
-
0.1 mM, 10% inhibition in the presence of 0.11 mM or 0.04 mM trypanothione disulfide
N-([2-[2,6-bis(phenylsulfanyl)phenyl]-1H-imidazol-5-yl]methyl)-N-ethylethanamine
N-benzyl-3-(2-chloro-10H-phenothiazin-10-yl)-N,N-dimethylpropan-1-aminium
-
-
N-benzyl-4-(2-chloro-4a,10a-dihydro-10H-phenothiazin-10-yl)-4-oxobutanamide
-
-
N-benzyl-6-bromo-2-(5-methylfuran-2-yl)quinoline-4-carboxamide
-
-
N-benzyolxycarbonyl-L-glutamyl(-benzoyl)-L-Leu-Ala
-
glutathione analogue, ASC-I-74B, inhibition of parasite growth and trypanothione reductase activity
N-benzyolxycarbonyl-L-glutamyl(-benzoyl)-L-Leu-Gly
-
glutathione analogue, ASC-I-74A, inhibition of parasite growth and trypanothione reductase activity
N-benzyolxycarbonyl-L-glutamyl(-benzoyl)-L-Val-Ala
-
glutathione analogue, ASC-I-75B, inhibition of parasite growth and trypanothione reductase activity
N-benzyolxycarbonyl-L-glutamyl(-benzoyl)-L-Val-Gly
-
glutathione analogue, ASC-I-75A, inhibition of parasite growth and trypanothione reductase activity
N-methyl-N-(2-oxo-2-(2-(phenylthio)phenylamino)ethyl)cyclohexanaminium
N-[(2E)-1-(2-phenoxyethyl)-3-(2-piperidin-1-ylethyl)-1,3-dihydro-2H-benzimidazol-2-ylidene]acetamide
-
IC50: 0.1 mM
N-[(4-chlorophenyl)(phenyl)methoxy]-8-methyl-8-azabicyclo[3.2.1]octan-3-imine
-
-
N-[(4-methylpiperazin-1-yl)methyl]-1-thiophen-2-ylmethanediamine
-
0.1 mM, 10% inhibition in the presence of 0.11 mM or 0.04 mM trypanothione disulfide
N-[2-(2-chloro-4a,10a-dihydro-10H-phenothiazin-10-yl)-2-oxoethyl]aniline
-
-
N-[2-(phenylsulfanyl)phenyl]-2-[(phenylsulfonyl)amino]propanamide
N-[2-[(4-bromophenyl)sulfanyl]-5-chlorophenyl]-3-(4-methylpiperazin-1-yl)propanamide
-
5% inhibition at 0.1 mM
N-[2-[(4-chlorophenyl)sulfanyl]phenyl]-2-(1,3-dioxo-1,3,3a,4,7,7a-hexahydro-2H-isoindol-2-yl)acetamide
N-[2-[(4-chlorophenyl)sulfanyl]phenyl]-2-phenylacetamide
-
IC50: 0.0368 mM
N-[2-[(4-chlorophenyl)sulfanyl]phenyl]-4-nitrobenzamide
-
IC50: 0.0445 mM
N-[2-[(4-chlorophenyl)sulfanyl]phenyl]benzamide
-
IC50: 0.0496 mM
N-[2-[(4-chlorophenyl)sulfanyl]phenyl]butanamide
-
IC50: 0.0305 mM
N-[2-[(4-chlorophenyl)sulfanyl]phenyl]propanamide
-
IC50: 0.0316 mM
N-[2-[(7-methoxy-2-acridinyl)amino]-6-(phenylsulfanyl)benzyl]-2-(4-methyl-1-piperazinyl)acetamide
N-[2-[(7-methoxy-2-acridinyl)amino]-6-(phenylsulfanyl)benzyl]-2-(4-methyl-1-piperazinyl)ethanimidamide
N-[2-[(7-methoxy-4a,9a-dihydroacridin-2-yl)amino]-6-(naphthalen-2-ylsulfanyl)benzyl]-2-(4-methylpiperazin-1-yl)acetamide
N-[2-[(7-methoxy-4a,9a-dihydroacridin-2-yl)amino]-6-(naphthalen-2-ylsulfanyl)benzyl]-N2,N2-dimethylglycinamide
N-[2-[(7-methoxy-4a,9a-dihydroacridin-2-yl)amino]-6-(pyridin-2-ylsulfanyl)benzyl]-2-(4-methylpiperazin-1-yl)acetamide
N-[2-[(7-methoxy-4a,9a-dihydroacridin-2-yl)amino]-6-(pyridin-2-ylsulfanyl)benzyl]-N2,N2-dimethylglycinamide
N-[2-[(naphthalen-1-ylacetyl)amino]ethyl]-4-[[(3-nitrophenyl)(oxo)acetyl]amino]piperidine-4-carboxamide
-
0.1 mM
N-[3-(4-amino-butylamino)-propyl]-O-[(E)-3-[3-((E)-3-[N-[3-(4-amino-butylamino)-propyl]aminooxy]-propenyl)-benzofuran-5-yl]-allyl]-hydroxylamine
-
benzofuranyl-based acyclic bis-polyamine analogue of lunarine with a planar bicyclic benzofuranyl scaffold, inhibition mechanism
N-[3-(4-methyl-piperazin-1-yl)-propyl]-O-[(E)-3-[3-((E)-3-[N-[3-(4-methyl-piperazin-1-yl)-propyl]aminooxy]-propenyl)-benzofuran-5-yl]-allyl]-hydroxylamine
-
benzofuranyl-based acyclic bis-polyamine analogue of lunarine with a planar bicyclic benzofuranyl scaffold, inhibition mechanism
N-[3-([2-[(4-chlorophenyl)sulfanyl]phenyl]amino)propyl]-4-(diphenylmethoxy)-N,N-dimethylanilinium
-
-
N-[3-([2-[(4-chlorophenyl)sulfanyl]phenyl]amino)propyl]-N,N-dimethylanilinium
-
-
N-[4-(benzyloxy)benzyl]-3-(2-chloro-10H-phenothiazin-10-yl)-N,N-dimethylpropan-1-aminium
-
-
N-[5-chloro-2-(phenylsulfanyl)phenyl]-3-(4-methylpiperazin-1-yl)propanamide
-
0% inhibition at 0.04 mM
N-[5-chloro-2-(phenylthio)phenyl]-3-(4-methylpiperazine-1-yl)-propanamidine
N1,N9-bis-(L-arginyl(2,2,5,7,8-pentamethylchroman-6-sulfonamide))-norspermidine
-
non-competitive inhibitor
N1,N9-bis-(L-tryptophanyl)-norspermidine
-
competitive inhibitor
N1,N9-bis-(L-tryptophanyl-L-arginyl(2,2,5,7,8-pentamethylchroman-6-sulfonamide))-norspermidine
-
non-competitive inhibitor
N1,N9-bis-(L-tryptophanyl-L-arginyl)-norspermidine
-
non-competitive inhibitor
N1-L-arginyl(2,2,5,7,8-pentamethylchroman-6-sulfonamide)-N9-acetyl-norspermidine
-
-
N1-L-arginyl(2,2,5,7,8-pentamethylchroman-6-sulfonamide)-N9-hexanoyl-norspermidine
-
-
N1-L-arginyl(2,2,5,7,8-pentamethylchroman-6-sulfonamide)-N9-L-arginyl-norspermidine
-
non-competitive inhibitor
N1-L-arginyl(2,2,5,7,8-pentamethylchroman-6-sulfonamide)-norspermidine
-
-
N1-L-arginyl-N9-acetyl-norspermidine
-
-
N1-L-arginyl-N9-hexanoyl-norspermidine
-
-
N1-L-arginyl-norspermidine
-
-
N1-L-tryptophanyl-L-arginyl(2,2,5,7,8-pentamethylchroman-6-sulfonamide)-N9-acetyl-norspermidine
-
-
N1-L-tryptophanyl-L-arginyl(2,2,5,7,8-pentamethylchroman-6-sulfonamide)-N9-hexanoyl-norspermidine
-
-
N1-L-tryptophanyl-L-arginyl(2,2,5,7,8-pentamethylchroman-6-sulfonamide)-norspermidine
-
-
N1-L-tryptophanyl-L-arginyl-N9-acetyl-norspermidine
-
-
N1-L-tryptophanyl-L-arginyl-N9-hexanoyl-norspermidine
-
-
N1-L-tryptophanyl-L-arginyl-N9-L-tryptophanyl-L-arginyl(2,2,5,7,8-pentamethylchroman-6-sulfonamide)-norspermidine
-
non-competitive inhibitor
N1-L-tryptophanyl-L-arginyl-norspermidine
-
-
N1-L-tryptophanyl-N9-acetyl-norspermidine
-
-
N1-L-tryptophanyl-N9-hexanoyl-norspermidine
-
-
N1-L-tryptophanyl-norspermidine
-
-
N1N8-bis(dihydrocaffeoyl)spermidine
-
-
N4-(3-chloroacridin-9-yl)-N1,N1-diethylpentane-1,4-diamine
-
-
N4-(6-chloro-2-methoxyacridin-9-yl)-N1,N1-diethylpentane-1,4-diamine
N4-allyl benzofuroxan-5-carboxaldehyde thiosemicarbazone
-
9% of inhibition at a inhibitor dose of 0.1 mM, 13% of inhibition at a inhibitor dose of 0.04 mM
N5-(3-chloroacridin-9-yl)-N1,N1-diethylhexane-1,5-diamine
-
-
NaCl
-
below 5% remaining activity at 1 M
NADPH
-
NADPH inhibits the enzyme at higher concentration and during longer incubation times, enzyme can be protected by NADP+
naphtho[1,2-b]furan-4,5-dione
-
-
naphtho[2,3-b]furan-4,9-dione
-
-
nifuraxide
-
increases oxidation of the enzyme
nifuroxime
-
increases oxidation of the enzyme
nifurprazine
-
increases oxidation of the enzyme
nifurtimox
nitrofurazone
numismine
Lunaria biennis
-
0.1 mM
oxidized 3-acetylpyridine adenine nucleotide
-
wild-type and mutant E201D and E201Q
-
panepoxydone
-
95% inhibition of trypanothione reductase
Pentamidine
-
growth inhibition
pentostam
-
growth inhibition
perphenazine
-
-
phenothiazines
-
-
-
phenyl(1-(piperidin-1-yl)cyclohexyl)methanone
-
-
phenylarsenoxide
-
+ NADPH
pindobind
-
-
Plumbagin
plumbagin derivatives
-
potassium antimony tartrate
-
assay containing 10% vol. methanol
prochlorperazine
-
-
promazine
-
-
quebrachamine
-
compound is an alkaloid scaffold lead in the search for inhibitors
-
Quinacrine
quinacrine mustard
-
enzyme and inhibitor first forms a reversible complex, then irreversible inactivation of NADPH-reduced and oxidized enzyme occurs, enzyme contains 2 interacting binding sites in the active site for the inhibitors, 2 inhibitor molecules per enzyme monomer are bound, addition of 2-mercaptoethanol prevents inactivation up to 25 mM, clomipramine strongly protects th enzyme from inactivation
spermidine
-
-
spermidine derivatives
-
derivatives of 2-amino-diphenylsulfide + phenothiazine
-
spermine
-
-
spermine derivatives
-
derivatives of 2-amino-diphenylsulfide + phenothiazine
-
tert-butyl 4'-(benzo[b]thiophen-2-yl)-1,4'-bipiperidine-1'-carboxylate
-
-
tert-butyl 4'-cyano-1,4'-bipiperidine-1'-carboxylate
-
-
tert-butyl-L-Leu-L-Arg-L-Arg-7-amido-4-methylcoumarin
-
reversible and competitive inhibition
tert-butyl-L-Leu-L-Lys-L-Arg-7-amido-4-methylcoumarin
-
reversible and competitive inhibition
tetrahydrolunarine
Lunaria biennis
-
0.1 mM
tetrahydrolunarinol
Lunaria biennis
-
0.1 mM
thio-NADP+
-
wild-type and mutant E201D and E201Q
thioridazine
-
-
trans-4-[3-(3,4-dichlorophenyl)indan-1-yl]morpholine
-
-
trans-benzyl-[3-(3,4-dichlorophenyl)-6-methoxyindan-1-yl]amine
-
-
trans-N-[3-(3,4-dichlorophenyl)indan-1-yl]-4-methylbenzenesulfonamide
-
-
trans-N-[3-(3,4-dichlorophenyl)indan-1-yl]acetamide
-
-
trans-[3-(3,4-dibromophenyl)-6-methoxyindan-1-yl]-(3-methylbutyl)amine
-
-
trans-[3-(3,4-dichlorophenyl)-6-methoxyindan-1-yl]-(3-methylbutyl)amine
-
-
trans-[3-(3,4-dichlorophenyl)indan-1-yl]-(3,4-dichlorobenzyl)amine
-
-
trans-[3-(3,4-dichlorophenyl)indan-1-yl]-(3-methylbutyl)amine
-
-
trans-[3-(3,4-dichlorophenyl)indan-1-yl]-(4-aminobenzyl)amine
-
-
trans-[3-(3,4-dichlorophenyl)indan-1-yl]-(4-chlorobenzyl)amine
-
-
trans-[3-(3,4-dichlorophenyl)indan-1-yl]-(4-dimethylaminobenzyl)amine
-
-
trans-[3-(3,4-dichlorophenyl)indan-1-yl]-(4-methoxybenzyl)amine
-
-
trans-[3-(3,4-dichlorophenyl)indan-1-yl]-(4-methylbenzyl)amine
-
-
trans-[3-(3,4-dichlorophenyl)indan-1-yl]octylamine
-
-
trans-[3-(4-chlorophenyl)-6-methoxyindan-1-yl]-(3-methylbutyl)-amine
-
-
trans-[3-(4-methoxyphenyl)-6-methoxyindan-1-yl]-(3-methylbutyl)amine
-
-
trans-[3-(4-methylphenyl)-6-methoxyindan-1-yl]-(3-methylbutyl)-amine
-
-
Trifluoperazine
trifluoroperazine
-
-
Trifluperazine
-
-
triflupromazine
-
-
triostam
-
assay containing 10% vol. methanol
Urea
-
1 mM urea has no significant effect on activity whereas 50% enzyme inhibition is observed at 750 mM, enzyme after treatment with urea below 500 mM regains about 95% activity
[(2,2'-bipyridine)Au(OH)2][PF6]
-
-
-
[6-benzyloxycarbonylamino-1,6-bis-(dimethylcarbamoylmethyl-carbamoyl)-hex-3-enyl]-carbamic acid benzyl ester
-
-
[6-benzyloxycarbonylamino-1,6-bis-(dimethylcarbamoylmethyl-carbamoyl)-hexyl]-carbamic acid benzyl ester
-
-
[Au((S)-4-Bn-2-(pyridin-2-yl)-4,5-dihydro-oxazole)Cl2][PF6]
-
-
-
[Au((S)-4-iPr-2-(pyridin-2-yl)-4,5-dihydro-oxazole)Cl2][PF6]
-
-
-
[Au2(bipy)2(m-O)2](PF6)2
-
-
-
[Cl2AuIII(2-(2'-pyridyl)benzimidazole)AuI(PPh3)](PF6)
-
-
-
[[(7-nitro-2,1,3-benzoxadiazol-4-yl)methyl]sulfanyl]methyl phenylcarbamate
-
reversible. Compound inhibits parasite proliferation with EC50 values between 50 and 5 microM
additional information
-